Workflow
菲鹏携手圣湘,聚焦 AI 分子酶创新研发与产品解决方案

Group 1 - The strategic partnership between Fipeng Bio and Shengxiang Bio focuses on the innovation and development of AI molecular enzymes and diagnostic solutions, aiming to create more accurate and reliable next-generation diagnostic solutions [1][2] - The collaboration seeks to leverage AI technology to enhance molecular enzyme development, addressing the limitations of traditional enzyme development methods, which include long development cycles and low optimization efficiency [1][2] - Shengxiang Bio is recognized as a leading enterprise in molecular diagnostics, with a strong emphasis on clinical insights and industrialization capabilities, while Fipeng Bio is a key player in the upstream life sciences sector, providing high-performance core raw materials for in vitro diagnostics [3][4] Group 2 - The partnership represents an exploration of the "AI + industrial transformation" innovation model, aiming to unlock the potential of AI in core raw materials for in vitro diagnostics and accelerate the conversion of innovative product solutions [2] - Shengxiang Bio is listed on the Sci-Tech Innovation Board and is among the top 100 global medical device companies, committed to becoming a leader in gene technology and supporting the national precision medical system [3] - Fipeng Bio, established in 2001, is a global leader in the upstream in vitro diagnostics sector, providing reagent core materials and solutions to over 2,500 diagnostic companies across 68 countries and regions [4]